Abstract
Patient reported outcome (PRO) data is being used to support labeling claims of products’ effects on patients’ functional status, experience of care, symptoms and symptom burden, and health related quality of life (HRQoL). This study reviewed PRO information reported in labels for novel drug approvals (NDAs) approved from 2016 to 2021 and compared findings to previously published results from 2006 to 2015.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
